AZIMUDDIN KAZI: Open Payments
NPI 1750321428 · STRATFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,545 in 125 payments from 21 companies in 2025. Trend: 2023 $2,579 · 2024 $2,315 · 2025 $2,545
Food & beverage: $2,545
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 15 | $301 |
| UCB, Inc. | 13 | $265 |
| ABBVIE INC. | 12 | $240 |
| SK Life Science, Inc. | 10 | $225 |
| ACADIA Pharmaceuticals Inc | 9 | $201 |
| Corium, LLC | 6 | $185 |
| Lundbeck LLC | 16 | $178 |
| ARGENX US, INC. | 7 | $160 |
| Tris Pharma Inc | 6 | $113 |
| Genentech USA, Inc. | 4 | $106 |
Products named: Qelbree, NUPLAZID, Azstarys, VYEPTI, VYVGART HYTRULO, Briviact, QULIPTA, BOTOX.
Industry payments across CT — which companies pay providers there.
